Podcast: Supply chains, obesity drugs, and patents dominate Q1 earnings trends
With pharma and medtech Q1 earnings season now at a close, some sector areas performed better than others. In this…
08 May 2026
AI-guided labs are approaching full autonomy
Taking a cue from the automotive industry, the biopharma sector has been increasingly focused on autonomous capabilities as a means towards improved accuracy, reproducibility, and efficiency in research and development…
07 May 2026
Podcast: Autonomous labs redefine the role of biopharma researchers
Advances in robotics and artificial intelligence (AI) are leading to a rise of autonomous biopharma labs—entities that can undertake biomedical research and development (R&D) with greater precision, consistency, and efficiency.…
05 May 2026
Non-viral gene therapies emerge as key players amid viral safety bottlenecks
Cell and gene therapies (CGTs) have long been heralded for their potential to transform outcomes of patients with complex, hard-to-treat diseases, with several of these medicines offering previously unattainable long-term…
30 Apr 2026
EU’s Joint Clinical Assessment system still finding its footing
In April, Ipsen’s Ojemda (tovorafenib) secured European Commission (EC) approval for the treatment of relapsed or refractory paediatric low-grade glioma. Notably, this approval is the first to initiate a 30-day…
24 Apr 2026
The slow march of clinical biomarkers to become surrogate endpoints
Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming surrogate endpoints, which can provide a measure of a treatment’s…
20 Apr 2026
Magazine: Digital twins become the new battleground for CDMOs
Contract Development and Manufacturing Organisations’ (CDMOs) expansion into more complex biopharmaceuticals, gene therapy and advanced product sectors is prompting a competitive position shift. This month’s cover feature examines the role…